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nant), Plasma/Albumin-Free Method (rAHF-PFM), was devel-
oped as an alternative treatment option for patients with hemo-
philia A. However, there is concern that this new technology
contributes signiﬁcant cost to the health care of these patients.
This model was developed to delineate the economic impact of
rAHF-PFM on a health care plan’s budget. METHODS: Payer
perspective is utilized for the analysis under a one-year time
horizon. The economic impact of the introduction of rAHF-PFM
was determined using average wholesale price. Estimates of
hemophilia A prevalence, factor VIII utilization, treatment regi-
mens, and clinical outcomes were derived from published litera-
ture. Migration from previous therapies (i.e., Helixate,
Kogenate, Recombinate, ReFacto, pdFVIII) to rAHF-PFM (17%
of patients) was based on equivalent market shares. Numerous
sensitivity analyses were performed to demonstrate the robust-
ness of the ﬁndings. RESULTS: In a 1,000,000 member plan, fol-
lowing introduction of rAHF-PFM, with 82.5% on-demand use
(30IU/kg/bleed with 16.8 bleeds/year) and 17.5% prophylactic
use (60IU/kg/week with 6.6 bleeds/year), it is estimated that
overall annual factor VIII treatment cost is $3,835,191, an
annual increase of $39,268 ($0.003 per member per month
increase). CONCLUSIONS: While there is heightened concern
regarding the potential budget impact of new technologies in
health care, this model demonstrates that rAHF-PFM can be pro-
vided to patients with relatively modest impact on a health care
plan’s budget.
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OBJECTIVES: While treatment options for hemophilia A have
provided effective disease management and have greatly
increased life expectancy, the Medical and Scientiﬁc Advisory
Council (MASAC) of the National Hemophilia Foundation has
recommended that “all efforts should be made to remove human
albumin from recombinant factor VIII products” to obviate lin-
gering concerns regarding the potential for viral transmission
through the use of factor VIII concentrates. To delineate the eco-
nomic value of a plasma/albumin-free factor VIII product, the
ﬁscal impact attributable to such a product was determined
under assumed emergence of a novel infectious blood/plasma
borne virus. METHODS: A deterministic model was developed
incorporating age-adjusted and proportionally weighted median
present-value (1999) annual expense estimates for the manage-
ment of HIV and AIDS for males, proportion of the hemophilia
A population infected due to the emergence of a novel blood
(plasma) borne virus (5%), fractional expense of that observed
with HIV/AIDS (5%), and the number of bleeding events expe-
rience by a given individual per year (i.e., international units of
factor VIII administered). Analyses were conducted for individ-
uals weighing 20-, 50-, and 80-kg. RESULTS: Under the assump-
tion of the emergence of a novel infectious blood (plasma) borne
virus, the model revealed a savings potential (p < 0.05) with the
use of a plasma/albumin-free factor VIII product relative to use
of a plasma/albumin-containing product, ranging from $0.06 per
IU (80kg male, 12 bleeding episodes/year) to $0.48 per IU 
(20kg male, 6 bleeding episodes/year), equating to a potential
cost-avoidance of $1742 to $6967 per year (present value).
CONCLUSIONS: Antihemophilic Factor (recombinant),
Plasma/Albumin-Free Method (rAHF-PFM) offers hemophilia A
patients a treatment regimen meeting MASAC recommendations
which eliminates the risk of infection from human and animal
protein additives with potential economic savings stemming
from avoidance of future costs associated with infections trans-
mitted through factor replacement therapy.
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OBJECTIVE: The residual risk of transmitting current and
emerging infectious blood-borne pathogens via blood transfu-
sion persists despite recent blood safety advances. The INTER-
CEPT Blood System (IBS) for platelets has been developed to
further reduce these pathogen transmission risks during platelet
transfusions. The objective of this study was to assess the cost-
effectiveness of using single-donor (aphaeresis) platelets (SDP)
processed with IBS in Japan. METHODS: A literature-based
decision analysis model was used to assess the cost-effectiveness
of the IBS in four patient populations that account for most of
the platelet usage in Japan: 1) a 10-year old male with acute lym-
phocytic leukaemia (ALL); 2) a 50-year old male with non-
Hodgkin’s lymphoma (NHL); 3) a 60-year old male undergoing
heart bypass surgery (CABG); and 4) a 70-year old female under-
going a hip arthroplasty. Pathogen exposure included HIV, HCV,
HBV, HTLV-I, bacterial sepsis, emerging and migrating
pathogens. The model compared projected quality-adjusted life-
year saved (QALY) and costs for patients receiving untreated vs.
treated platelets. RESULTS: The incremental cost per QALY
gained by using SDP + IBS vs. SDP ranged from
¥96,248,673–¥793,899,885. Inclusion of a hepatitis C-like
emerging pathogen beneﬁt signiﬁcantly improved the cost effec-
tiveness to ¥20,534,864–¥434,648,944. The model was most
sensitive to mortality from bacterial contamination and the risk
rate of emerging and/or migrating pathogens. The model was rel-
atively insensitive to transmission risks from currently known
viruses. CONCLUSION: The cost-effectiveness of IBS for
platelets is comparable and mostly better to that of other blood
and general safety interventions (e.g., mini-pool NAT testing,
chemical regulations, trafﬁc safety measures) that are accepted
as valuable in Japan. Thus, pathogen inactivation with IBS may
be considered as a desirable strategy to further improve the safety
of platelet transfusions and a valuable insurance against the
threat of new emerging and migrating pathogens.
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OBJECTIVES: Extended prophylaxis with the synthetic pen-
tasaccharide fondaparinux for one month versus one week in hip
fracture surgery has been shown to reduce the risk of venous
thromboembolism (VTE) by 96% in the Penthifra Plus trial. The
cost-effectiveness of extended prophylaxis with fondaparinux
from a Swiss perspective still remains to be determined.
METHODS: We developed a decision analytic cost-effectiveness
model comparing the use of fondaparinux for four weeks versus
one week from a health care perspective. The analyses were per-
formed for patients undergoing hip fracture surgery (HFS) and
